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onitoring in Patients Treated With
pironolactone for Congestive Heart Failure
eyur B. Shah, MD,* Krishnamurti Rao, BS,† Robert Sawyer, MD,‡ Stephen S. Gottlieb, MD, FACC§
altimore, Maryland
OBJECTIVES This study was designed to determine the adequacy of monitoring patients receiving
spironolactone as well as spironolactone’s relationship to hyperkalemia.
BACKGROUND After the Randomized Aldactone Evaluation Study (RALES) demonstrated a 30% mortality
benefit for treating severe heart failure patients with spironolactone, acceptance of this drug
was overwhelming. Hyperkalemia and worsening renal function were rare in RALES, but
laboratory monitoring was frequent. In clinical practice, the incidence of hyperkalemia and
worsening renal function and adequacy of follow-up is unknown.
METHODS We reviewed the monitoring of congestive heart failure (CHF) patients with spironolactone
initiation after publication of RALES. All potassium and creatinine determinations at
baseline and within three months following therapy initiation were assessed. Increased
potassium was defined as any [K] 5.5 mEq/l and severe hyperkalemia as any [K] 6.0.
RESULTS A total of 840 patients had new prescriptions for spironolactone. Of these, 91% had baseline
laboratory values, and 34% did not have any serum potassium or creatinine determined within
three months. Patients seen in the cardiology clinic were more likely to have appropriate
follow-up (p  0.001). Of 551 patients with follow-up laboratory values determined, 15%
developed hyperkalemia and 6% developed severe hyperkalemia. Fifty-one patients (9%)
developed renal dysfunction, of whom 25 developed hyperkalemia within three months.
Hyperkalemia developed in 48 of 138 (35%) patients with baseline creatinine1.5 mg/dl and
12 of 19 (63%) with baseline creatinine 2.5 mg/dl.
CONCLUSIONS Many patients treated with spironolactone for CHF do not receive needed follow-up of
potassium or creatinine concentrations, although hyperkalemia and renal dysfunction are
common. Elevated baseline creatinine predicts patients at high risk. Physician education of
the risks of spironolactone and the need for follow-up is essential. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.01046:845–9) © 2005 by the American College of Cardiology Foundation
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Cn 1999, the Randomized Aldactone Evaluation Study
RALES) demonstrated a 30% decrease in mortality for
reating congestive heart failure (CHF) patients with spi-
onolactone (1). The benefit was seen in patients already
eceiving background therapy with angiotensin-converting
nzyme (ACE) inhibitors. Previously used in heart failure to
romote diuresis, spironolactone was readily accepted as an
nexpensive agent to treat severe systolic dysfunction (2,3).
owever, the potassium-sparing effects of spironolactone
ose a great risk for retaining potassium and subsequent
atal arrhythmias, especially in patients taking other medi-
ations affecting the renin-angiotensin-aldosterone system.
ndeed, Juurlink et al. (4) observed that following publica-
ion of the RALES trial there was a marked increase in
rescriptions for spironolactone, as well as rates of
yperkalemia-associated mortality and morbidity greater
han those observed before the RALES trial.
There are many reasons that could explain more safety
roblems with spironolactone use in clinical practice than in
ontrolled trials. For example, inappropriate patient selec-
From the *Department of Medicine, †Division of Cardiology, ‡Department of
torhinolaryngology-Head and Neck Surgery, and §Division of Cardiology, The
niversity of Maryland School of Medicine and the Baltimore Veterans Affairs
edical Center, Baltimore, Maryland.T
Manuscript received February 2, 2005; revised manuscript received May 11, 2005,
ccepted May 15, 2005.ion based on systolic function, New York Heart Associa-
ion heart failure classification, background medication, and
nderlying renal disease has been reported in a previous
etrospective study (5). We hypothesized that inadequate
onitoring of serum potassium concentrations and renal
unction might also contribute to an increased incidence of
yperkalemia after initiation of spironolactone. We re-
iewed the monitoring patterns for hyperkalemia and renal
ysfunction in CHF patients receiving spironolactone after
ublication of the RALES trial.
ETHODS
esign. This was a retrospective study using the Veterans
ffairs Information System Technology and Architecture
VISTA) database. We reviewed in-patient and outpatient
lectronic records for patients with CHF who received
utpatient prescriptions for spironolactone at the following
aryland VA hospitals or clinics: Baltimore, Fort Howard,
ambridge, Perry Point, and Glen Burnie.
dentification of data. We extracted patient information
nd records from VISTA or through the Computerized
atient Record System (CPRS) interface program. Health
are providers at the VA hospital centers use VISTA and
PRS to access and update medical records for patients.
he information in the database is available to health care
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Laboratory Monitoring for Spironolactone September 6, 2005:845–9roviders when prescribing spironolactone. Any prescrip-
ions written at the VA medical center are entered into the
atabase before being dispensed from the pharmacy.
We identified a cohort with an in-patient or outpatient
iagnosis of heart failure (International Classification of
iseases 428.x) in VISTA. Consecutive patients who re-
eived their initial prescription for spironolactone between
eptember 2, 1999, and April 1, 2004, were included. The
ata collection for follow-up laboratory data was through
uly 7, 2004, to allow evaluation of a three-month follow-up
eriod. A total of 898 patients fit these criteria.
We defined background medications to include prescrip-
ions providing medications up to 30 days before or after
rescribing spironolactone. We determined cardiovascular
edication prescriptions, including ACE inhibitors, angio-
ensin receptor blockers, beta-adrenergic antagonists, loop
iuretics, potassium supplements, and cardiac glycosides.
We obtained ejection fraction data from echocardiogram
r multiple gated acquisition scan reports. For values re-
orted in closed-end ranges, we calculated a mean ejection
raction. For values reported as open-end ranges, we used
efined lower or upper limits in our calculations.
The database provided in-patient and outpatient lab data
hat could be used to analyze monitoring patterns. The most
ecent serum potassium and creatinine values, up to one year
efore prescribing spironolactone, defined baseline values.
eak serum creatinine and potassium concentrations were
btained for the first three months after spironolactone was
ispensed. Identical to the RALES trial, serum potassium
oncentrations 5.5 mEq/l defined hyperkalemia, and lev-
ls 6.0 mEq/l defined severe hyperkalemia. Rising serum
reatinine concentrations from baseline to a value 2.5
g/dl defined renal dysfunction. We reviewed in-patient
nd outpatient electronic charts for patients without
ollow-up laboratory data in the three months after initiat-
ng therapy.
The University of Maryland Medical Center Institu-
ional Review Board and the Veterans Affairs Research and
evelopment Committee reviewed and approved this
roject.
tatistical analysis. The data are expressed as mean SD.
two-tailed Student t test was used to compare continuous
ariables. Chi-square analysis was used to compare discrete
ariables. The package used was SPSS for Windows, version
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  congestive heart failure
CPRS  Computerized Patient Record System
RALES Randomized Aldactone Evaluation Study
VISTA  Veterans Affairs Information System
Technology and Architecture1.5 (SPSS Inc., Chicago, Illinois).
f
sESULTS
e identified 898 patients with a diagnosis of CHF and a
ew prescription for spironolactone. Thirty-four patients
ere excluded from the monitoring analysis because they
iscontinued care at the study institutions during the
hree-month follow-up period. Twenty-four patients were
xcluded because of death within three months of starting
pironolactone. A total of 840 patients were included in the
onitoring analysis.
We found that 556 patients (66%) had serum potassium
nd creatinine values monitored within three months fol-
owing initiation of spironolactone (Fig. 1). Five of these
atients had values obtained outside of the VA system, with
esults noted by the prescribing VA physician. Thus, data
rom 551 patients were available for determination of
yperkalemia frequency. Of the 840 patients, 284 (34%) did
ot have any follow-up laboratory data. Of the 284 patients,
he prescribing physician did not order follow-up laboratory
ata for 149, 41 failed to follow up for scheduled laboratory
raws, and 94 had prescriptions filled at VA while also
nder the care of outside physicians. There is no evidence
hat the prescribing VA physician was aware of any labora-
ory values obtained elsewhere.
Patients with serum potassium concentrations measured
ithin three months of initiating spironolactone were more
ikely to be receiving the following cardiovascular medica-
ions: ACE inhibitors or angiotensin receptor blockers,
eta-adrenergic receptor blockers, and digoxin (all p 
.05). These patients were younger (69  11 years vs. 71 
1 years, p 0.05) and had lower baseline serum potassium
oncentrations (4.3  0.5 mEq/l vs. 4.4  0.5 mEq/l, p 
.05) (Table 1).
Of 551 patients with follow-up data, 83 patients (15%)
eveloped hyperkalemia ([K] 5.5 mEq/l); 31 (6%) were
lassified as severe hyperkalemia ([K]6.0 mEq/l). Patients
hat developed hyperkalemia had higher baseline potassium
4.7  0.7 mEq/l vs. 4.3  0.5 mEq/l, p  0.001) and
igure 1. The laboratory monitoring follow-up of patients with heart
ailure started with spironolactone. One-third of the patients did not have
erum potassium checked within three months of drug initiation.
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September 6, 2005:845–9 Laboratory Monitoring for Spironolactoneerum creatinine concentrations (1.8  0.9 mg/dl vs. 1.2 
.5 mg/dl, p  0.001) (Table 2).
Fifty-one patients (9%) developed renal dysfunction; 25
f these patients (49%) also developed hyperkalemia within
hree months of initiating spironolactone. The incidence of
yperkalemia increased with increasing baseline serum cre-
tinine (Fig. 2): hyperkalemia occurred in 35% (48 of 138)
f patients with a baseline serum creatinine 1.5 mg/dl,
6% (22 of 48) if 2.0 mg/dl, and 63% (12 of 19) if 2.5
g/dl (as compared with 9%, 13%, and 14% if the baseline
reatinine was 1.5, 2.0, and 2.5 mg/dl, respectively [all p
0.001]). The mean follow-up serum potassium concen-
ration was 5.2 0.8 mEq/l if the baseline serum creatinine
oncentration was 1.5 mg/dl and 4.7  0.7 mEq/l if
reatinine 1.5 mg/dl (p  0.001); 5.5  0.9 mEq/l if
reatinine 2.0 mg/dl and 4.7  0.7 mEq/l if creatinine
2.0 mg/dl (p  0.001); and 5.8  0.9 mEq/l if creatinine
2.5 mg/dl and 4.8  0.7 mEq/l if creatinine 2.5 mg/dl
p  0.001).
ISCUSSION
onitoring. This study demonstrates marked deviation of
onitoring for hyperkalemia in clinical practice as com-
Table 1. Comparison of Patients With and W
Age (yrs)
Men
Ejection fraction (%)
Baseline potassium (mEq/l)
Baseline creatinine (mg/dl)
Baseline medications
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Angiotensin receptor blocker or angiotensin-
converting enzyme inhibitor
Beta-blocker
Loop diuretic
Digoxin
Potassium supplement
*p  0.05 as compared to patients with follow-up.
Table 2. Comparison of Patients With and W
H
Age (yrs)
Men
Ejection fraction (%)
Baseline potassium (mEq/l)
Baseline creatinine (mg/dl)
Baseline medications
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Angiotensin receptor blocker or angiotensin-
converting enzyme inhibitor
Beta-blocker
Loop diuretic
Digoxin
Potassium supplement*p  0.001 as compared to patients with hyperkalemia.ared with that performed in clinical trials. This may
xplain the increased mortality secondary to hyperkalemia
bserved since publication of the RALES trial. In the
ALES trial, patients initially treated with spironolactone
ad serum potassium and creatinine concentrations mea-
ured at 4, 8, and 12 weeks, and then every 3 months for up
o 1 year. We observed in this study that only two-thirds of
he patients had serum laboratory values obtained in the first
hree months after initiating spironolactone. The remaining
4% were prescribed spironolactone by a physician without
ny follow-up monitoring. Although a portion (14%) of this
roup failed to present for lab draws, a larger percentage
53%) were never scheduled for follow-up. Thirty-three
ercent were prescribed spironolactone by a doctor who
new the patient was also being followed outside of the VA
edical system and may have assumed that appropriate
onitoring was taking place. However, with no documen-
ation of knowledge of laboratory values, it must be assumed
hat the prescription occurred without assurance of safety.
Inadequate monitoring for side effects when prescribing
utpatient cardiovascular medication is not a unique occur-
ence. Physicians have previously exhibited variable (and
nadequate) monitoring patterns with other medications,
t Follow-Up
ow-Up (n  556) No Follow-Up (n  284)
69  11 71  11*
550 (99%) 281 (99%)
 15 (n  429) 35  14 (n  112)
 0.5 (n  501) 4.4  0.5* (n  202)
 0.8 (n  510) 1.4  0.6 (n  202)
441 (79%) 194 (68%)*
34 (6%) 32 (11%)*
476 (86%) 226 (78%)*
387 (70%) 177 (62%)*
508 (91%) 251 (88%)
351 (63%) 148 (52%)*
171 (31%) 83 (29%)
t Hyperkalemia
kalemia (n  83) No Hyperkalemia (n  473)
70  10 69  11
83 (100%) 467 (99%)
 14 (n  70) 35  15 (n  360)
 0.7 (n  80) 4.3  0.5* (n  425)
 0.9 (n  80) 1.2  0.4* (n  434)
72 (87%) 371 (78%)
4 (5%) 30 (6%)
76 (92%) 401 (85%)
54 (65%) 333 (70%)
75 (90%) 436 (92%)
50 (60%) 301 (64%)
26 (31%) 145 (31%)ithou
Foll
35
4.3
1.3ithou
yper
34
4.7
1.8
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Laboratory Monitoring for Spironolactone September 6, 2005:845–9ncluding antiarrhythmic medications (6). However, we are
ot aware of any reports of the frequency of monitoring for
asic electrolytes when spironolactone is initiated.
Patients with follow-up were more likely to be receiving
edications proven to be of benefit in patients with heart
ailure: ACE inhibitors or angiotensin receptor blockers,
eta-blockers, and digoxin. This suggests that patients with
lose laboratory follow-up also had more appropriately
reated heart failure. Although it is possible that doctors
ere more concerned that patients receiving ACE inhibitors or
igoxin might develop hyperkalemia, the higher frequency of
se of beta-blockers appears to reflect better care in patients
eceiving more frequent laboratory assessments.
Although qualities inherent to a retrospective design limit
he accuracy of our observations, the results remain alarm-
ng. These data illustrate the difficult translation of con-
rolled clinical trials into clinical practice. In the RALES
rial, study participants were closely followed with frequent
ab work and medication dosage adjustments. We did not
bserve vigilant monitoring in the clinical environment.
uurlink et al. (4) described a disturbing rise in incidences of
atal and non-fatal hyperkalemia since publication of the
ALES trial, which we believe is due partly to relaxed
utpatient surveillance of potassium concentrations.
yperkalemia. Of 551 patients with three-month fol-
ow-up lab data, 15% developed hyperkalemia and 6%
eveloped severe hyperkalemia. In contrast, the RALES
rial reported severe hyperkalemia following spironolactone
nitiation in only 2% of patients. Several factors may
ontribute to the observed high rate of hyperkalemia. Most
mportantly, investigators in the RALES trial enforced a
trict surveillance regimen over the cohort with appropriate
edication adjustment when rising potassium levels were
bserved. Thus, potential episodes of severe hyperkalemia
igure 2. The incidence of hyperkalemia associated with various baseline
erum creatinine concentrations. Note that even a modest increase in
reatinine concentration increases the risk of hyperkalemia.ay have been precluded by early intervention. In addition, firequent physician visits allow management of related med-
cal issues, including volume status that may contribute to
he overall health of the individual. As previously de-
cribed, we did not observe such strict monitoring in clinical
ractice.
The exclusion criteria used in the RALES trial may have
lso limited the prevalence of hyperkalemia. These criteria
re not applied in clinical practice. Of the patients we
tudied, 105 would have been excluded from therapy in the
ALES trial because of baseline serum creatinine concen-
rations of 2.5 mg/dl or greater and/or a baseline serum
otassium concentration of 5.0 mEq/l or greater. Predict-
bly, approximately one-half (28 of 60) of these individuals
eveloped hyperkalemia. Also, patients receiving spirono-
actone in clinical practice tend to be older than those in the
ALES trial. The mean age in our population was 70  11
ears as compared to 65  12 years in the RALES trial.
lder patients will have lower glomerular filtration rates
nd, therefore, an increased predisposition for potassium
etention.
When compared with patients enrolled in the RALES
rial, more patients in the present study were receiving
eta-blocker therapy (68% vs. 11%). Beta-adrenergic recep-
or antagonism can suppress the renin-angiotensin-
ldosterone system by inhibiting renin secretion from the
uxtaglomerular apparatus, predisposing patients to potas-
ium retention. This may explain the high rate of severe
yperkalemia (5.5% at one year) in the Eplerenone Post-
cute Myocardial Infarction Heart Failure Efficacy and
urvival Study (EPHESUS), a large trial showing the
enefits of the selective mineralocorticoid receptor antago-
ist eplerenone in post-myocardial infarction patients with
ackground therapy that included beta-blockers (7).
enal dysfunction. As a safety measure, researchers ex-
luded from the RALES trial individuals with a serum
reatinine concentration 2.5 mg/dl. The present study
upports the limited use of spironolactone in patients with
ncreased renal impairment. Patients with higher baseline
erum creatinine concentration had higher rates of hyper-
alemia and greater mean follow-up potassium con-
entrations.
Of great concern is our finding that a baseline serum
reatinine concentration ranging as low as 1.5 to 1.9 mg/dl
an still predict a high risk (35%) of developing hyperkale-
ia. After excluding patients who would not have qualified
or therapy in the RALES trial, we found that individuals
ith serum creatinine concentrations between 1.5 and 2.5
g/dl have a 30% rate of hyperkalemia, compared with 9%
n patients with baseline creatinine concentrations below 1.5
g/dl. These results suggest that patients with renal dys-
unction (measured by elevated serum creatinine concentra-
ion) are at higher risks of developing hyperkalemia and
equire vigilant monitoring.
tudy limitations. Because the present study is a retrospec-
ive chart review, there are factors that might influence the
ndings. Some patients may have discontinued medications
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September 6, 2005:845–9 Laboratory Monitoring for Spironolactoneithout appropriate physician documentation in the data-
ase and not required further monitoring for elevated
erum potassium concentrations. Conversely, inclusion of
n-patient labs may overestimate the outpatient physicians’
ffort to monitor serum potassium concentrations.
It is also possible that outside physicians were monitoring
he patients. However, if the prescribing physician did not
now these data, the risk to the patient would still be high.
e believe it unlikely that many prescribing physicians
ould know outside laboratory values and not record this
nformation.
Considering that we accessed only records of dispensed
edications, without actual follow-up evaluating medica-
ion adherence, it is possible that some cases of hyperkale-
ia are falsely associated with spironolactone. Of greater
oncern is that poor medication adherence or discontinua-
ion of spironolactone without documentation has errone-
usly minimized our findings of the number of medicated
atients who develop hyperkalemia; the percentage of pa-
ients taking spironolactone that develop hyperkalemia may
ctually be higher than what is calculated in this study. Our
xclusion of patients who died in the three-month
ollow-up period removes the “high-risk” individuals from
nalysis and may also lead to an underestimate of the risks
f spironolactone.
We do not believe that the observations in this study
oncerning safety are limited to the VA hospitals, as recent
linical models describe the quality of care within the VA
ealth care system as exceeding that of Medicare fee-for-
ervice beneficiaries (8). Furthermore, most physicians at
he Baltimore VA are staff physicians at the adjoining
niversity of Maryland Hospital; thus, the behavior of
hysicians observed in this study likely reflects that of other
nstitutions and is not specific for the VA. Indeed, the
xcellent database of the VA system not only permits quality
mprovement analyses such as the present report, but can
lso make interventions possible to ensure that physicians
erform required monitoring of patients who receive high-
isk medications. Electronic reminders or mandatory mon-
toring with prescriptions could be considered. Our findings
oint to the likelihood that the real-world environment
dversely shifts the risk-benefit of spironolactone compared
ith that observed in the RALES trial. It is probable that bymproving monitoring, the results of therapy would more
losely approximate the outcome of the trial.
onclusions. Although mineralocorticoid receptor antag-
nism has been shown to decrease cardiac remodeling and,
n turn, improve cardiac function and mortality, spironolac-
one use produces a higher risk for hyperkalemia than the
ALES trial predicts. Hyperkalemia after initiating spi-
onolactone is a common occurrence, and surveillance by
edical professionals is poor. In addition to appropriate
atient selection, limiting hyperkalemia and potential
eadly arrhythmias requires close monitoring after initiating
herapy. Patients with increased renal impairment, even if
nly minor, require especially attentive monitoring and
eliable follow-up. Systems should be implemented to
nsure that patients receiving spironolactone are carefully
elected and closely monitored.
eprint requests and correspondence: Dr. Stephen S. Gottlieb,
niversity of Maryland Hospital, Division of Cardiology, 22
outh Greene Street, Baltimore, Maryland 21201. E-mail:
gottlie@medicine.umaryland.edu.
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